What do research and development have in common?
The answer: Robert Roskamp, a philanthropist and Sarasota-based developer of senior living facilities. Understanding first hand the effects these diseases can have on patients and their families after his brother was diagnosed with schizophrenia, Roskamp dedicated his life to finding cures and treatments of such diseases. In 2003, their quest led to the creation of The Roskamp Institute in Sarasota, Florida, where some of the world’s most cutting-edge research is conducted on neurological disorders.
Since opening its doors, The Roskamp Institute, a 501(c)(3) nonprofit organization, has been a leader in the global effort to better understand and ultimately cure debilitating diseases of the mind. The foundation for the Institute’s work was set more than a decade ago by Roskamp’s two lead researchers, Drs. Michael Mullan and Fiona Crawford. They were key members of a pioneering team of scientists who, in the early 1990s, discovered that the onset of Alzheimer’s was, among other things, directly related to the accumulation of a protein called ß-amyloid.
The Roskamp Institute’s Alzheimers work is dedicated to developing medications and therapeutic treatments that will reduce or slow the toxic accumulation of ß-amyloid. A promising new treatment, was developed by our researchers and is currently being tested in a Phase III clinical study in Europe, with results expected in the early-2018.